Tradestie Institutional Equity Comparison Engine
AKTS vs DTIL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DTIL Overall Edge
DTIL Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Precision BioSciences, Inc. Common Stock (DTIL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, AKTS trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus DTIL at 11.8x Forward P/E and -80.3% operating margin (+37272.4% YoY). In options structure, AKTS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against DTIL sits in CONSOLIDATION (14th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
DTIL
AKTS N/M vs DTIL 11.8x Fwd P/E
Growth & Margin Winner
DTIL
Op Margin N/A vs -80.3% ยท YoY N/A vs +37272.4%
Momentum & Technical Winner
DTIL
1Y -26.4% vs +25.7% ยท 52W Pos 12% vs 49%
Options & Structure Winner
DTIL
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (14th %ile IV)
AKTS
US Equity
AKTS
Institutional Equity
$16.49
-0.78% 1D
Market Cap
N/A
1M Return
+9.5%
1Y Return
-26.38%
Forward P/E
N/M
Unified AI Score
30.6 / 100
SELL
Tech 20.0
Fund 36.0
Flow 50.0
Mom 40.0
DTIL
NASDAQ
Precision BioSciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.36
-2.78% 1D
Market Cap
$306.9M
1M Return
+27.47%
1Y Return
+25.73%
Forward P/E
11.8x
Unified AI Score
41.0 / 100
SELL
Tech 15.0
Fund 43.0
Flow 70.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
AKTS -26.38%
DTIL +25.73%
Spread: +114.01 pp (DTIL Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
AKTS TTM Op. Margin: N/A
DTIL TTM Op. Margin: -80.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKTS vs DTIL. Trailing 12-month operating profitability (AKTS N/A vs DTIL -80.3%) and valuation multiples (AKTS N/M vs DTIL 11.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AKTS | DTIL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $306.9M | Larger Scale | DTIL |
| Trailing P/E Ratio Valuation | N/M | 32.2x | Lower Multiple | DTIL |
| Forward P/E Ratio Valuation | N/M | 11.8x | Lower Multiple | DTIL |
| Revenue Growth (YoY) Growth | N/A | +37272.4% | Higher Growth | DTIL |
| Operating Margin (TTM) Profitability | N/A | -80.3% | Higher Margin | DTIL |
| Net Profit Margin Profitability | N/A | -85.6% | Higher Margin | DTIL |
| Return on Equity (ROE) Capital Efficiency | N/A | -115.3% | Higher ROE | DTIL |
| 52-Week Range Position Momentum | 12% ($14โ$34) | 49% ($4โ$11) | Stronger Trend | DTIL |
| Beta / 30D Volatility Risk Regime | 1.36ฮฒ ยท 66% Vol | 0.31ฮฒ ยท 126% Vol | Lower Realized Risk | AKTS |
| Unified Institutional Score Composite Signal | 30.6 / 100 (SELL) | 41.0 / 100 (SELL) | Higher Composite | DTIL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full AKTS vs DTIL Buy Guide
AKTS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
DTIL
CONSOLIDATION
129d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither AKTS nor DTIL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.